R&D (Research and Development)
Use the R&D (Research and Development) Calculator → Try the R&D (Research and Development) Quiz →R&D (Research and Development) expense is the cost of activities aimed at discovering new products, processes, or technologies. Under US GAAP, nearly all R&D costs are expensed immediately - reducing reported profit even though the spending may generate competitive advantages for years.
- R&D expense covers research (generating new knowledge) and development (converting knowledge into products); under US GAAP (ASC 730), nearly all R&D is expensed immediately rather than capitalised as an asset.
- R&D sits below Gross Profit alongside SG&A, so it reduces Operating Profit (EBIT) but does not affect Gross Margin - critical when comparing margins across R&D-intensive and non-R&D peers.
- R&D intensity (R&D / Revenue) ranges from under 2% in consumer staples to 15-25% in pharmaceuticals and semiconductors; always compare within sector, not across industries.
- Under IFRS (IAS 38), development costs (not research) may be capitalised if six specific criteria are met, creating a GAAP/IFRS divergence that inflates reported EBIT for IFRS-reporting peers.
- Cutting R&D to hit a short-term earnings target immediately improves reported profit while quietly depleting the future product pipeline and competitive position.
What is R&D (Research and Development)?
R&D expense covers all costs directly associated with research (generating new knowledge) and development (converting that knowledge into products or processes). Under US GAAP (ASC 730), nearly all R&D costs must be expensed as incurred - meaning they reduce profit in the period they occur rather than being capitalised as an asset. This treatment depresses reported earnings in the current period even when R&D spending generates long-lived competitive advantages.
R&D sits as a separate line item below Gross Profit on the income statement, alongside SG&A, and above Operating Profit (EBIT). Unlike COGS (which varies with production volume) and SG&A (which covers overhead and sales), R&D is a discretionary investment in future capability. A company can cut R&D to hit a short-term earnings target - but doing so sacrifices the product pipeline and long-term competitiveness.
R&D intensity (R&D as a percentage of revenue) varies enormously by industry. Pharmaceutical and biotech companies may spend 15-25% of revenue on R&D to advance drug pipelines. Semiconductor companies run at 15-20%. Enterprise software runs at 10-20%. By contrast, consumer staples and retail may spend under 2%. When comparing EBIT margins across companies, always check whether differences in R&D intensity explain part of the gap.
R&D (Research and Development) explained to a beginner
Imagine you run a bakery and you hire a baker specifically to experiment with new recipes - trying different ingredients, testing new ovens, developing a gluten-free line. Those wages do not go into the cost of today's bread. Instead, the entire experimentation cost is written off as an expense immediately, even though the resulting recipe might generate revenue for years.
That is essentially what R&D expense is: money a company spends on experiments that might - or might not - become profitable products in the future. Under US accounting rules, almost all R&D is expensed immediately, which depresses current profits even when the spending is building real future value. This is why pharmaceutical companies can report operating losses while simultaneously building drug pipelines worth tens of billions of dollars.
When to use R&D (Research and Development)
Compare R&D-to-revenue ratios across direct peers to assess investment intensity and strategic posture. When analysing EBIT, consider what profitability would look like at a lower R&D level - but recognise this would reduce future innovation. In valuation, some analysts use R&D capitalisation models to estimate the intangible asset value of accumulated R&D investment on the balance sheet.
Worked examples for R&D (Research and Development)
This table quickly gives you the overview you need to understand R&D (Research and Development) and its most important comparisons.
| Sector | Typical R&D / Revenue | Primary R&D purpose |
|---|---|---|
| Large pharma / biotech | 15-25% | Drug pipeline, clinical trials |
| Semiconductors | 15-20% | New chip architectures |
| Enterprise software (SaaS) | 10-20% | Product development |
| Automotive | 4-6% | Vehicle platforms, EV transition |
| Consumer staples | 1-3% | Formulation, packaging |
| Retail | <1% | Process improvements |
Common pitfalls
The most common pitfall is confusing R&D expensing with software development capitalisation. Under ASC 350-40, internal-use software development costs in the application development stage are capitalised - not expensed. This creates an inconsistency: a company building internal tools capitalises the cost, while one developing a product to sell to customers expenses it immediately. Under IFRS (IAS 38), development costs (but not research costs) may be capitalised if six specific criteria are met, creating a further divergence between GAAP and IFRS-reporting peers.
Global pharmaceutical R&D spending reached approximately $245 billion in 2022, up from $137 billion a decade earlier, reflecting the escalating cost of bringing new drugs through regulatory approval - a typical new drug now requires over $2 billion and 10-15 years from discovery to approval. (IQVIA Institute, 2023)
Frequently asked questions about R&D (Research and Development)
Is R&D a capital expenditure or an operating expense?
Under US GAAP, nearly all R&D is an operating expense, expensed immediately (ASC 730). One exception is software development: internal-use software development costs are capitalised under ASC 350-40 once the application development stage begins. Under IFRS (IAS 38), development costs - as distinct from research costs - may be capitalised if six criteria are met, creating a divergence between GAAP and IFRS companies.
Why do pharmaceutical companies have such high R&D?
Developing a new drug from discovery to FDA approval typically requires 10-15 years and over $2 billion in investment, with a high failure rate - roughly 90% of compounds that enter clinical trials never receive approval. Pharma companies must sustain continuous investment to replenish their pipeline as existing drugs lose patent protection. Blockbuster drugs can generate returns that justify the investment, but only a small fraction of R&D spending ever recovers its cost.
How does R&D affect EBIT versus EBITDA?
R&D reduces both EBIT and EBITDA equally, since both metrics include R&D as a line-item operating cost. Unlike Depreciation & Amortization - which EBITDA adds back - there is no standard add-back for R&D. The only scenario where R&D has different impacts is if a company capitalises some R&D costs and amortises them; in that case EBITDA adds back the amortisation while EBIT does not.
What is R&D capitalisation?
R&D capitalisation is the practice of treating R&D costs as a long-lived asset rather than an immediate expense - estimating the balance sheet value of accumulated R&D investment (minus amortisation). It is not standard GAAP practice, but is used by valuation researchers (notably Damodaran) to estimate the true intangible asset base of technology and pharma companies. It can significantly change calculated returns on capital (ROIC) for R&D-intensive businesses.
Quiz: how well do you know R&D expense?
1. Under US GAAP (ASC 730), how are nearly all R&D costs treated?
2. Where does R&D appear on the income statement?
3. From the sector table, which two industries have the highest typical R&D intensity as a percentage of revenue?
4. What accounting inconsistency does the pitfalls section identify between US GAAP and IFRS for R&D costs?
5. According to the FAQ, in what one scenario does R&D have a different impact on EBIT versus EBITDA?